Q2 FY2026 · ended Jun 30, 2026 · Revenue $398,657, -2.0% YoY · Filed Aug 13, 2026
VolitionRx Limited (VNRX) files with the SEC under industry code 2835, In Vitro & In Vivo Diagnostic Substances. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $398,657 and a net loss of $7.3 million. Free cash flow was -$5.2 million. As of Jun 30, 2026 it held $2.8 million in cash and investments and $7.7 million in total debt.
Revenue
$398,657
-2.0% vs year-ago quarter
Net income
$-7.33M
-16.6% vs year-ago quarter
Operating cash flow
$-5.16M
+17.6% vs year-ago quarter
Free cash flow
$-5.16M
+18.6% vs year-ago quarter
EPS
$-0.85
+30.3% vs year-ago quarter
Dividend per share
None
Shares outstanding
13.65M
-87.3% vs year-ago quarter
Net cash
$-4.95M
Q2 FY2026
Operating margin
-791.2%
TTM
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- VNRX (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Henderson, NV
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 93314
- Former names
- VOLITIONRX LTD (until Oct 27, 2026); STANDARD CAPITAL CORP (until Sep 29, 2011)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $398,657 | $985,076 | $447,034 | $627,277 | $406,688 |
| Operating income | -$4.2M | -$5.3M | -$4.8M | -$5.1M | -$6.3M |
| Net income | -$7.3M | -$6.7M | -$6.3M | -$5.4M | -$6.3M |
| Diluted EPS | -$0.85 | -$0.97 | -$0.05 | -$0.05 | -$1.22 |
| Operating cash flow | -$5.2M | -$5.3M | -$5.5M | -$3.6M | -$6.3M |
| Free cash flow | -$5.2M | -$5.3M | -$5.5M | -$3.6M | -$6.3M |
| Total assets | $8.3M | $9.0M | $6.9M | $6.4M | $8.7M |
| Total liabilities | $41.8M | $42.4M | $42.5M | $42.4M | $41.8M |
| Stockholders' equity | -$32.2M | -$32.0M | -$34.2M | -$34.6M | -$31.8M |
| Cash and investments | $2.8M | — | $1.1M | $200,000 | $2.3M |
| Total debt | $7.7M | $8.1M | $7.6M | $7.5M | $7.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Other events
|
Oct 27, 2026 | Oct 23, 2026 |
| 8-K |
Current report
Unregistered share sale
|
Sep 25, 2026 | Sep 22, 2026 |
| 8-K |
Current report
Unregistered share sale
|
Sep 15, 2026 | Sep 9, 2026 |
| 8-K |
Current report
Other events
|
Sep 14, 2026 | Sep 11, 2026 |
| 8-K |
Current report
Material agreement
|
Sep 2, 2026 | Sep 2, 2026 |
| 8-K |
Current report
Unregistered share sale
|
Sep 2, 2026 | Aug 27, 2026 |
All 1004 VolitionRx Limited SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.